Home

Seer, Inc. - Class A Common Stock (SEER)

2.2800
+0.1000 (4.59%)
NASDAQ · Last Trade: Jun 7th, 1:24 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Competitors to Seer, Inc. - Class A Common Stock (SEER)

10x Genomics TXG +3.40%

10x Genomics specializes in genomics solutions, offering technologies that enable high-resolution analysis of biological systems, which competes directly with Seer, Inc.'s focus on proteomics and biomarker discovery. 10x Genomics' advantage lies in its established market presence and extensive product portfolio that caters to various genomic sequencing needs, which positions it as a leader in the genomics space and a strong competitor to Seer's innovative proteomic analysis tools.

Bio-Rad Laboratories BIO +0.05%

Bio-Rad Laboratories offers a diverse range of products and services including those for life sciences research and clinical diagnostics, which overlap with the proteomics solutions that Seer, Inc. aims to provide. Known for its robust portfolio, Bio-Rad's competitive strength lies in its long-standing industry presence, extensive customer relationships, and wide distribution network. This established reputation and resource access grants Bio-Rad a prominent position, making it a leading competitor against Seer, particularly in laboratory settings.

Illumina ILMN +0.50%

Illumina leads in genetic sequencing technologies, which is a vital aspect of precision medicine and bioinformatics that overlaps with Seer, Inc.’s proteomic analysis offerings. With a strong focus on genomic solutions and a well-established customer base, Illumina benefits from significant economies of scale and extensive research collaborations. This allows Illumina to maintain a competitive edge over newer companies like Seer, which are still expanding their market presence and technological offerings.

Proteona

Proteona focuses on developing single-cell genomics and proteomics solutions, making them a direct contender against Seer, Inc. in the field of biomarker discovery and precision medicine. The company harnesses advanced technologies to analyze immune responses and cell behavior, thus targeting similar markets as Seer. While Proteona has unique methodologies that set it apart, it lacks the broad market recognition and established customer base that Seer is building, giving Seer a competitive edge in outreach and brand trust.

Thermo Fisher Scientific TMO +0.89%

Thermo Fisher Scientific operates in a similar domain, providing analytical instruments, reagents, and consumables for life sciences and diagnostics, which encompasses the same markets that Seer targets. With its expansive product offerings and significant financial backing, Thermo Fisher has a competitive advantage through its wide range of solutions and substantial research investments. This market dominance makes it a formidable competitor to Seer, as it can swiftly adapt to market needs and invest in innovations.